A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
← catalyst calendarNCT06995820 · readout in 34 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
136estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-06 | actual | When the study began enrolling |
| Primary completion | 2026-09-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-23 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-30 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: AZD1613
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs) and serious AEs.
measured AEs: Part A: From Day 1 to Final Follow-up (Day 105); Part B: From Day 1 to Final Follow-up (Day 161); SAEs: Part A: From Screening (Day -28 to Day -2) to Final Follow-up visit (Day 105) Part B: From Screening (Day -28) to Final Follow-up visit (Day 161)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed